Get the Stockscreener App
5.73
1.88%
-0.11
After Hours:
5.73
Emergent Biosolutions Inc Stock (EBS) Latest News
Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08 - The Manila Times
Just Awarded: Emergent BioSolutions Grants Major 72,882 Share Package to Strategic New Hire - StockTitan
Emergent BioSolutions: Attractive Biotech With Proven Business Clouded By Washington Funding Issues - Seeking Alpha
Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg - The Manila Times
Breakthrough: New High-Dose Naloxone Spray Gets Health Canada Green Light as Overdose Crisis Persists - StockTitan
Syngene concludes acquisition of biologics manufacturing facility from Emergent BioSolutions - Medical Dialogues
Emergent BioSolutions sells Baltimore facility to Syngene By Investing.com - Investing.com South Africa
Emergent BioSolutions Completes Sale of Baltimore-Bayview Facility to Syngene International - Marketscreener.com
Emergent BioSolutions sells Baltimore facility to Syngene - Investing.com India
Emergent Biosolutions finalizes sale of Baltimore-Bayview manufacturing site to Syngene International - Marketscreener.com
Emergent BioSolutions Finalizes Sale of Baltimore-Bayview Manufacturing Site to Syngene International - The Manila Times
Emergent BioSolutions Strategic Win: $36.5M Facility Sale While Securing Future Production Rights - StockTitan
Syngene concludes the acquisition of Biologics Manufacturing Facility from Emergent BioSolutions Inc. - Equity Bulls
Emergent BioSolutions secures $27 million in MCM orders - Investing.com
Emergent BioSolutions Announces Approximately $27 Million in Incremental Sales to Supply International Customers with Five Critical Medical Countermeasure Products - The Manila Times
Emergent BioSolutions Expands Global Reach with $27M Medical Defense Deal - StockTitan
India-based Syngene acquires its first US biologics site - Manufacturing Dive
Emergent BioSolutions to invest in Rocketvax for vaccine developments - MSN
Emergent BioSolutions to sell Baltimore-Bayview manufacturing site for $36.5M - MSN
Emergent signs financial investment agreement with Swiss Rockets - Yahoo
Emergent BioSolutions Reinforces its Commitment to Expanding Access to NARCAN® Nasal Spray by Supporting Organizations with New Opioid Overdose Preparedness Programs - The Manila Times
Emergent BioSolutions Reinforces its Commitment to Expanding Access to NARCAN® Nasal Spray by ... - The Bakersfield Californian
First OTC Narcan Program Targets High-Risk Construction Workers to Combat Overdose Crisis - StockTitan
Emergent BioSolutions director Zoon sells $57,300 in stock By Investing.com - Investing.com Australia
Emergent BioSolutions director Fowler sells $204,050 in stock By Investing.com - Investing.com Australia
Emergent BioSolutions director Fowler sells $204,050 in stock - Investing.com India
Emergent BioSolutions director Zoon sells $57,300 in stock - Investing.com
Emergent Bio and Rocketvax in investment deal and partnership - The Pharma Letter
Emergent BioSolutions and Rocketvax Announce Investment Agreement - Contract Pharma
Emergent Biosolutions And Rocketvax Announce Investment Agreement And Pursuit Of A Strategic Relationship For Next-Generation Product Candidates - Marketscreener.com
Emergent BioSolutions to Invest in Swiss Rockets, Rocketvax -March 12, 2025 at 08:40 am EDT - Marketscreener.com
Emergent BioSolutions, Rocketvax announce investment agreement - TipRanks
Emergent BioSolutions and Rocketvax Ltd Announce Strategic Investment and Partnership to Advance Next-Generation Vaccine Development - Nasdaq
Emergent BioSolutions and Rocketvax Announce Investment - GlobeNewswire
Emergent BioSolutions and Rocketvax Announce Investment Agreement and Pursuit of a Strategic Relationship for Next-Generation Product Candidates - GlobeNewswire Inc.
Rhumbline Advisers Trims Stock Position in Emergent BioSolutions Inc. (NYSE:EBS) - Defense World
Syngene buys its first manufacturing facility in US for USD36.5 million - Medical Dialogues
India's Syngene International acquires first US biologics facility for $36.5 mln - Reuters
Emergent BioSolutions Sells Baltimore Facility to Syngene - TipRanks
Gaithersburg's Emergent BioSolutions to sell Baltimore plant for $36.5M - Washington Business Journal
Drug manufacturer to sell Baltimore plant for $36.5M - The Business Journals
Emergent BioSolutions drops after Syngene buys co's unit for $36.5 mln - TradingView
India's Syngene International acquires first US biologics facility for $36.5 million - Yahoo Finance
Emergent to Sell Baltimore-Bayview Facility for $36.5 Million -March 10, 2025 at 10:28 am EDT - Marketscreener.com
Emergent BioSolutions Announces Sale of Baltimore-Bayview Manufacturing Site to Syngene International - citybiz
Emergent BioSolutions to sell Baltimore-Bayview facility for $36.5M - TipRanks
Emergent BioSolutions Divests Baltimore Plant While Securing Future Production Rights - StockTitan
Emergent BioSolutions’ (EBS) Buy Rating Reiterated at HC Wainwright - Defense World
Q1 Earnings Estimate for EBS Issued By HC Wainwright - Defense World
Emergent BioSolutions Inc. (NYSE:EBS) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - Yahoo Finance
Is Emergent BioSolutions (NYSE:EBS) Weighed On By Its Debt Load? - Simply Wall St
2.31%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):